Use of oncolytic virus to treat tumors

The use of an oncolytic vesicular stomatitis virus (VV1) engineered to express human interferon beta (IFNP) and a sodium iodide symporter (NIS), combined with a PD-1 targeting antibody, addresses the toxicity issues of current chemotherapy by enhancing immunotherapy response and achieving pathologic complete response in triple-negative breast cancer without doxorubicin and cyclophosphamide.

WO2026241313A1PCT designated stage Publication Date: 2026-11-19VYRIAD INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027871
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current chemotherapy regimens for early-stage breast cancer, such as doxorubicin and cyclophosphamide (AC), are associated with significant toxicity and unfavorable risk-benefit profiles, necessitating the development of less toxic, neoadjuvant strategies that maintain oncologic efficacy.

Method used

Administration of an oncolytic vesicular stomatitis virus (VV1) engineered to express human interferon beta (IFNP) and a sodium iodide symporter (NIS) prior to standard of care (SOC) treatment for triple-negative breast cancer, combined with a PD-1 targeting antibody, to induce tumor inflammation and enhance immunotherapy response.

Benefits of technology

This approach achieves pathologic complete response (pCR) without requiring doxorubicin and cyclophosphamide, reducing toxicity and improving treatment outcomes for triple-negative breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027871_19112026_PF_FP_ABST
    Figure US2026027871_19112026_PF_FP_ABST
Patent Text Reader

Abstract

In aspects, the present disclosure provides a method of treating a tumor, the method comprising: (I) administering a virus to the tumor, and (II) performing standard of care (SOC) treatment for the tumor. Additional aspects are as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Leydig 775438Vyriad P-58-0031USE OF ONCOLYTIC VIRUS TO TREAT TUMORSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims the priority benefit of U.S. Provisional Patent Application No. 63 / 804,620, filed May 12, 2025; and U.S. Provisional Patent Application No.63 / 805,094, filed May 13, 2025; the disclosures of which are incorporated herein by reference in their entireties for all purposes.BACKGROUND

[0002] Doxorubicin (also known under the trade name Adriamycin) and cyclophosphamidebased chemotherapy (AC) has long been a cornerstone in the treatment of early-stage breast cancer, administered in both neoadjuvant and adjuvant settings. Although clinically effective, AC chemotherapy is associated with significant toxicity that can adversely affect both short- and long-term patient outcomes. Doxorubicin, an anthracycline, carries a well-characterized, dosedependent risk of cardiotoxicity, which may result in left ventricular dysfunction or congestive heart failure. Cyclophosphamide, an alkylating agent, is associated with additional risks, including hemorrhagic cystitis, ovarian insufficiency, infertility, and an elevated incidence of secondary hematologic malignancies, such as therapy-related leukemia. Furthermore, AC frequently induces profound myelosuppression, often necessitating hematologic support, and is commonly associated with severe gastrointestinal toxicity and complete alopecia — side effects that collectively impose a substantial burden on patient quality of life.

[0003] Treatment guidelines issued by the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) emphasize the importance of tailoring chemotherapy based on tumor biology, recurrence risk, and individual patient factors. The adoption of genomic profiling tools, such as Oncotype DX, has facilitated the identification of patient subgroups unlikely to benefit from cytotoxic chemotherapy. In such cases, the unfavorable toxicity profile of AC may outweigh its therapeutic benefit, particularly when alternative regimens with lower systemic toxicity are available. Nonetheless, AC continues to be routinely administered across broader patient populations, including some for whom its riskbenefit balance remains unclear.Leydig 775438Vyriad P-58-0032

[0004] The emergence of targeted neoadjuvant therapies offers a compelling opportunity to reduce or eliminate the use of AC in biomarker or otherwise defined breast cancer subtypes. If such regimens can achieve comparable pathological complete response (pCR) rates without the cumulative toxicity associated with anthracyclines and alkylating agents, they may support the development of less burdensome, more individualized treatment paradigms. Accordingly, there remains a critical clinical need for novel neoadjuvant strategies that enable chemotherapy de-escalation while preserving oncologic efficacy.

[0005] Currently, AC is indicated in certain subtypes of early-stage breast cancer treatment. There is an ongoing need to reduce the use of AC in breast cancer treatment.

[0006] There is an ongoing need in the art for treatments of breast cancer.BRIEF SUMMARY

[0007] In aspects, the present disclosure provides a virus for use in a method for neoadjuvant treatment of a tumor in a subject, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).

[0008] In aspects, the present disclosure provides a virus for use in a method of sensitizing a tumor in a subject to induce an enhanced immunotherapy response, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 is a schematic diagram of a proposed mechanism of an embodiment of a method of treatment showing a construct encoding an oncolytic vesicular stomatitis virus (VSV) engineered to express human interferon beta (IFNP) used in combination with a humanized programed death 1 (PD-1) antibody (cemiplimab).Leydig 775438Vyriad P-58-0033

[0010] FIG. 2 is an image of a schematic showing the experimental design for the I-SPY 2.2 trial of Voyager VI (VV1) and cemiplimab combination treatment (VVl+Cemiplimab) of different responsive predictive subtypes of HER2 tumors.

[0011] FIG. 3 shows the distribution of tumor biological response-predictive phenotype subtypes among tumors that were human epidermal growth factor receptor 2 negative (HER2) and either hormone receptor negative (negative for both estrogen receptor and progesterone receptor) (HR ) or hormone receptor positive (positive for estrogen receptor and / or progesterone receptor) (HR+), where the biological response-predictive phenotype subtypes were identified as immune positive or negative (indicating a predicted phenotype of benefiting from immunotherapy and inflamed, or not benefiting from immunotherapy and not inflamed, respectively), and DNA damage repair deficient (DRD) positive or negative (indicating a predicted phenotype of DNA damage repair deficient or not DNA damage repair deficient, respectively).

[0012] FIGS. 4A and 4B are schematic showing the experimental design for the VV1 and cemiplimab combination trial for HER2 tumors with different responsive predictive subtypes indicating how many doses of the VVl+cemibiplimab were administered to patients during Block A (FIG. 4A) and the experimental design for determining early escalation to Block B treatment based on functional tumor volume (FTV) as determined by MRI (FIG. 4B).

[0013] FIGS. 5A-5E are graphs showing the treatment efficacy of Wl+cemiplimab+SOC treatment compared to the dynamic control as density and pathological complete response (pCR). FIG. 5A shows the treatment efficacy of the VVl+cemiplimab alone (VVl+Cemi), with SOC treatment comprising paclitaxel plus carboplatin and pembrolizumab (T+C+Pembro), and with chemotherapy treatment with doxorubicin and cyclophasmamide (AC) and pembrolizumab (AC+Pembro) compared to Dynamic Control in HR Her2 tumors. FIG. 5B shows the treatment efficacy of the VVl+cemiplimab alone (VVl+Cemi), with SOC treatment comprising paclitaxel plus carboplatin and pembrolizumab (T+C+Pembro), and with chemotherapy treatment with doxorubicin and cyclophasmamide (AC) and pembrolizumab (AC+Pembro) compared to treatment with paclitaxel and AC (T / / AC) and Dynamic Control in HR+HER2 Immune DRD tumors. FIG. 5C shows the treatment efficacy of the VVl+cemiplimab alone (VVl+Cemi), with SOC treatment comprising paclitaxel plus carboplatin and pembrolizumab (T+C+Pembro), andLeydig 775438Vyriad P-58-0034with chemotherapy treatment with AC and pembrolizumab (AC+Pembro) in HR HER2 Immune DRD tumors. FIG. 5D shows the treatment efficacy of the VVl+cemiplimab alone (VVl+Cemi), with SOC treatment comprising paclitaxel plus carboplatin and pembrolizumab (T+C+Pembro), and with chemotherapy treatment with AC and pembrolizumab (AC+Pembro) in HER2 Immune+ tumors. FIG. 5E shows the treatment efficacy of the VVl+cemiplimab alone (VVl+Cemi), with SOC treatment comprising paclitaxel plus carboplatin and pembrolizumab (T+C+Pembro), and with chemotherapy treatment with AC and pembrolizumab (AC+Pembro) in HER.2 Immune DRD+ tumors.

[0014] FIGS. 6A and 6B are graphs showing adverse events for patients treated with VVl+cemiplimab by condition grade and number of patients for block A events (FIG. 6A) and for all block events (FIG. 6B) with a median follow up time of 28 days post-surgery. In FIG. 6A adverse event grade is scored in increasing severity from left to right with the least severe score being 1, up to a score of 3. In FIG. 6B adverse event grade is scored in increasing severity from left to right with the least severe score being 1, except for the infusion related reaction adverse event which begins with a grade 2 score, and each box to the right indicating an increased grad of severity up to grade 4.

[0015] FIGS. 7A and 7B are graphs show immune related adverse events for all patients treated with VVl+cemiplimab (FIG. 7A) and for patients treated with four doses of VVl+cemiplimab (FIG. 7B). In FIG. 7A adverse event grade is scored in increasing severity from left to right with the least severe score being 2, up to a score of 4. In FIG. 7B immune related adverse events are categorized by what block the immune event occurred during, Before Block A (1), during Block A (2), During Block B (3), During Block C (4), or Post Surgery (5). All terms including Rash, Rash maculo-papular, Dermatitis, Rash pustular, Rash maculopapular, Skin disorder, Dermatitis acneiform, Rash pruritic, Rash erythematous, Eczema, Urticaria, and Rash macular and have been combined under the term “Rash”. Drug-induced hepatitis, hepatitis, immunotherapy-related hepatitis, and autoimmune hepatitis have been combined under the term “autoimmune hepatitis”.Leydig 775438Vyriad P-58-0035DETAILED DESCRIPTION

[0016] In aspects, the present disclosure provides a method of treating a tumor, the method comprising, consisting of, or essentially consisting of: (1) administering a virus to the tumor, and (II) performing standard of care (SOC) treatment for the tumor.

[0017] In aspects, the present disclosure provides a method of sensitizing a tumor to induce an enhanced immunotherapy response, the method comprising, consisting of, or essentially consisting of: (i) administering a virus to the tumor, and (ii) performing standard of care (SOC) treatment for the tumor.

[0018] In aspects, the intratumoral injection of virus induces inflammation in the tumor. In aspects, the viral induced-inflammation of the tumor results in soreness, tenderness, tenseness, and / or swelling in the tumor that is patient-detectable by palpitation. Without wishing to be bound by theory it is believed that the inflammation of the tumor sensitizes the tumor to subsequent therapy.

[0019] In aspects, the tumor is human epidermal growth factor receptor 2 negative (HER2 ). In aspects, the tumor is progesterone receptor negative and estrogen receptor negative (HR ). In aspects, the tumor is HER.2 and HR (triple negative).

[0020] Any suitable method for determining the tumor receptor (e.g., HER2, progesterone receptor, estrogen receptor, etc.) is contemplated herein, including, but not limited to immunohistochemistry, fluorescence in situ hybridization (FISH), or others known in the art, such as Mukhtar et al. (“Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the LSPY2 Clinical Trial,” Ann. Surg. Oncol., 32(11) :8243-8253 (2025)), which is incorporated by reference herein.

[0021] In aspects, the tumor has a biological response-predictive subtype of immune low or negative. In aspects, the tumor has a biological response-predictive subtype of DNA repair deficiency (DRD) low or negative.

[0022] A biological response-predictive subtype can be determined based on pre-treatment gene expression and predicted response to different treatments. A tumor is determined to have an immune positive (Immune+) response-predictive subtype if the subject’s immune-tumor state is such that they are likely to respond to immunotherapy and immune low or immune negativeLeydig 775438Vyriad P-58-0036(Immune ) if their immune-tumor state is such that they are unlikely to respond to immunotherapy. A tumor is determined to have DNA repair deficient (DRD+) response-predictive subtype if response to a platinum agent with or without PARP-inhibition is likely and DNA repair deficiency low or negative if response to a platinum agent with or without PARP-inhibition is unlikely. . Biomarkers for biology response-predictive subtypes can be identified using microarrays known in the art, including but not limited to the 70 gene MammaPrint test, the 53 gene ImPrint test, and the 80 gene BluePrint test. In aspects, the immune response-predictive subtypes can be determined based on dendritic cell and STAT1 gene signatures, and B cell and mast cell gene signatures. In aspects, the DRD immune-response subtypes can be determined based on PARPi7 gene signatures and estrogen receptor gene signatures, progesterone receptor and estrogen receptor gene signatures, also referred to as luminal gene signatures, and basal gene signatures in tumors not driven by progesterone receptor, estrogen receptor, and HER2 receptor pathways.

[0023] In aspects, the virus is an oncolytic virus. In aspects, the virus is a recombinant vesicular stomatitis virus (VSV). Vesicular stomatitis virus (VSV) is a rhabdovirus, having a natural receptor of the low-density lipoprotein receptor (LDL-R) or very low density lipoprotein receptor (VLDL-R), which are expressed on the cell membrane of many types of cells.Rhabdoviruses are viruses within the family Rhabdoviridae . The viruses encode proteins denoted N (nucleoprotein), P (phosphoprotein), M (matrix protein), G (glycoprotein), and L (large protein, which is a polymerase), and the viruses appear to have a shape of a bullet when observed using electron microscopy. Dimensions of rhabdovirus virions can range from 100 nm to 430 nm in length and can range from 45 nm to 100 nm in diameter.

[0024] In aspects, the virus is engineered to express human interferon (IFNP). Without wishing to be bound by theory, it is believed that virus induced expression of IFNP activates anti-viral innate immune responses in non-tumor cells avoiding viral toxicity in healthy cells healthy while acting as a tumor suppressor by inhibiting growth of tumor cells and enhancing immunological response to tumor cells. In aspects, the virus is engineered to express a sodium iodide symporter (NIS). In aspects, the NIS induces accumulation of iodide in infected cells sufficient for imaging of cells infected by the virus. In aspects, the NIS induces accumulation of iodide in infected cells sufficient for radiotherapy targeted to the infected cells. In aspects, theLeydig 775438Vyriad P-58-0037virus is Voyager VI™ (VV1). VV1 is an oncolytic vesicular stomatitis virus engineered to express human IFNP to enhance cellular anti-tumor immune responses and tumor selectivity, and the human sodium iodide symporter (NIS) for virus tracking by SPECT imaging, as disclosed in e.g. International Patent Application PCT / US2011 / 050227, which is incorporated by reference herein. In aspects, the oncolytic virus is an Edmonston-Zagreb measles vaccine strain virus, such as disclosed by Forcic et al. (“An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer,” Vaccines, 12 (958): 1-8 (2024)), which is incorporated by reference herein. In aspects, the oncolytic virus is a genetically engineered herpesvirus, such as disclosed by Deng et al. (“Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy,” Journal of Medical Virology, 95: e28768 (2023)), which is incorporated by reference herein.

[0025] In aspects, a method of treating comprises administering a dose of virus as described herein and subsequently administering at least one additional dose of virus as described herein. The subsequent administration may be within hours, days, months, or years of the first administration, with scheduling to be determined by patient needs. Multiple rounds of subsequent administrations may be performed, using the same or different virus at the same or different doses as determined by the patient needs. In aspects, the virus is administered at a dose between 1E7 TCID50 and 1E11 TCID50, including 1E8 TCID 50, 1E9 TCID50, and 1E10 TCID50. Exemplary doses include, but are not limited to, 1E9 TCID50, 3E9 TCID50, 1E10 TCID50, 3E10 TCID50, and 1E11 TCID50. In aspects, subsequent administrations of the virus are administered at the same dose as the initial administration of the virus. In aspects, subsequent administrations of the virus are administered at a different dose than the initial administration of the virus. In aspects, the virus is administered at a dose between 1E7 TCID50 and 1E11 TCID50. In aspects, the virus is administered at a dose of 3E9 TCID50. In aspects, the virus is administered at a dose of 3E10 TCID50. In aspects, the administration of the virus is repeated every 21 days. In aspects, at least two doses are administered. In aspects, at least three doses are administered. In aspects, at least four doses are administered.

[0026] In aspects, the method comprises administering a programmed cell death 1 (PD-1) targeting antibody or antigen binding fragment thereof in combination with the virus. In aspects, the administration is simultaneous. In aspects, the administration is not simultaneous. In aspects,Leydig 775438Vyriad P-58-0038the PD-1 targeting antibody or antigen binding fragment thereof is an anti-PD-1 antibody or antigen binding fragment thereof or an anti-programmed cell death ligand 1 (PD-L1) antibody or antigen binding fragment thereof. In aspects, the PD-1 targeting antibody or antigen binding fragment thereof binds specifically to PD-1. In aspects, the PD-1 targeting antibody is cemiplimab, nivolumab, pembrolizumab, atezolizumab, or avelumab. In aspects, the method comprises administering a dose of a programmed cell death 1 (PD-1) targeting antibody or antigen binding fragment thereof in combination with the virus as described herein and subsequently administering at least one additional dose of the PD-1 targeting antibody or antigen binding fragment thereof in combination with the virus. The subsequent administration may be within hours, days, months, or years of the first administration, with scheduling to be determined by patient needs. Multiple rounds of subsequent administrations may be performed, using the same or different PD-1 targeting antibody or antigen binding fragment thereof at the same or different doses and using the same or different virus at the same or different doses and as determined by the patient needs. In aspects, the administration is intravenous. In aspects, the PD-1 targeting antibody or antigen binding fragment thereof is administered at a dose of 350 mg. In aspects, the administration of the PD-1 targeting antibody or antigen binding fragment thereof is repeated every 21 days. In aspects, at least two doses are administered. In aspects, at least three doses are administered. In aspects, at least four doses are administered. In aspects, the PD-1 targeting antibody is cemiplimab.

[0027] Programmed cell death- 1 (PD-1, also referred to as programmed death 1) is a coreceptor expressed on the surface of activated T-cells that mediates immunosuppression. The binding of PD-1 to one of its ligands, programmed cell death ligand 1 (PD-L1) or programmed cell death ligand 2 (PD-L2), results in the inhibition of a cytotoxic T-cell response. Increased expression of PD-L1 in the tumor microenvironment facilitates escape from the immune-surveillance mechanism (T-cell-induced anti-tumor activity). PD-lplays an important role in autoimmunity, tumor immunity and infectious immunity, and is thus an ideal checkpoint inhibitor (CPI) target for immunotherapy. Blocking PD-1 with antagonists, including monoclonal antibodies, has been studied in treatments of cancer and chronic viral infections. Blockade of PD-1 is also an effective and well tolerated approach to stimulating the immune response, and has achieved therapeutic advantage against various human cancers, including melanoma, renalLeydig 775438Vyriad P-58-0039cell cancer, and non-small cell lung cancer (NSCLC). See for example, the disclosures of Sheridan 2012, Nat. Biotechnol., 30:729-730; Postow et al., 2015, J Clin Oncol, 33:1974-1982; Chen et al., 2013, Nat. Rev. Immunol., 13:227-242; Riley, 2009, Immunol. Rev., 229:114-125; Dong et al., 1999, Nature Med., 5(12): 1365-1369; Zou, 2008, Nat. Rev. Immunol., 8:467-77; Ribas 2012, A7'1 / A7366:25 I7-25 I9; Watanabe et al., 2012, Clin. Dev. Immunol. Vol. 2012, Article ID: 269756; Wang et al., 2013, J. Viral Hep., 20:27-39; Flies et al., 2011, Yale J. Biol. Med., 84:409-421; Pardoll, 2012, Nature, 12:252-264; Freeman, 2008, PNAS, 105:10275-10276; and Francisco et al., 2010, Immunol. Rev., 236:219-242, which are each incorporated by reference herein. Monoclonal antibodies to PD-1 are known in the art and have been described, for example, in US 9987500, US 8008449, US 8168757, US 20110008369, US 20130017199, US 20130022595, WO 2006121168, WO 20091154335, WO 2012145493, WO 2013014668, WO 2009101611, EP 2262837, and EP 2504028, the disclosures of which are each incorporated by reference herein. Cemiplimab (also known as REGN2810; LIBTAYO®), for example, is a high-affinity, fully human, hinge-stabilized IgG4P antibody directed to the PD-1 receptor that potently blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2.

[0028] Refinements in conventional therapies such as chemotherapy, radiotherapy, surgery, and targeted therapies and recent advances in immunotherapies have improved outcomes in patients with advanced solid tumors. In the last few years, the FDA and European Medicines Agency have approved six CPI antibodies targeting programmed death receptor / ligand (PD- 1 / PD-L1), including atezolizumab, avelumab, durvalumab, nivolumab, cemiplimab and pembrolizumab, for the treatment of patients with multiple cancer types, mainly solid tumors (Gentzler et al., “Beyond Melanoma: Inhibiting The PD-1 / PD-L1 Pathway in Solid Tumors,” Immunotherapy, 5(5): 583-600 (2016) and Ribas et al., “Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy,” Cell, 170: 1109-1119.el0 (2017), which are incorporated by reference herein). These approvals have dramatically changed the landscape of cancer treatment. However, the majority of cancer patients, including the majority with tumors considered ‘sensitive’ to these agents, e g., melanoma, NSCLC, urothelial carcinoma, kidney cancer, and others, either do not respond or become resistant to these agents (Arora et al., “| Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors,” Adv. Ther., 36: 2638-2678 (2019), incorporatedLeydig 775438Vyriad P-58-00310by reference herein). In addition, some of the most prevalent tumors, colorectal, breast cancer and prostate cancer, have proven largely refractory to checkpoint inhibition (Borcherding et al., “Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer,” Journal of Molecular Biology, 430(14): 2014-2029 (2018), incorporated by reference herein).

[0029] Many immunotherapy treatments have demonstrated efficacy in only a selected subgroup of cancers, such as those expressing PD-L1 (GENETECH„Tecentriq®, Prescribing Information, 2025) / , with microsatellite instability (MSI) / mismatch repair (MMR) deficiency or high tumor mutational burden (Luchini et al., “ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1 / PD-L1 expression and tumour mutational burden: a systematic review-based approach,” Annals of Oncology, 30(8): 1232-1243 (2019), incorporated by reference herein), and even the novel targeted agents only address very small sub-populations across tumor types (BAYER HEALTHCARE PHARMACEUTICALS, Vitrakvi®, Prescribing Information, (2022), incorporated by reference herein). Indeed, despite considerable early success and relatively fewer side effects compared to other systemic therapies, the majority of cancer patients do not respond to checkpoint inhibitors (CPIs) or novel targeted therapies (Arora et al., (2019)). Blocking mAbs directed against checkpoint inhibitors such as programmed cell death l(PD-l) / programmed cell death ligand 1 (PD-L1) have been clinically approved for melanoma, renal cell carcinoma, non-small lung cancer and advanced metastatic cutaneous squamous cell carcinoma. Blocking PD-1 releases the break on T-cell activation, but its efficacy as a single agent often it is not sufficient to get tumor clearance and durable anti-tumor responses. The majority of current treatments, however, have a difficult time overcoming the inhibitory nature of the tumor microenvironment, thus failing to generate efficient tumor-specific T-cell activation and subsequent tumor cell killing. With effective treatments remaining scarce in patients with advanced solid tumors, there is an unmet medical need for more effective and less toxic therapies, such as combination therapies having synergistic mechanisms of action with the immune CPIs as disclosed herein.

[0030] In aspects, the SOC treatment is performed at least 21 days after the administration of the virus. In aspects, the SOC treatment comprises an intravenous administration of paclitaxel at a dose of 80 mg per m2 (mg / m2), wherein the administration is repeated every 7 days. In aspects,Leydig 775438Vyriad P-58-00311the SOC treatment comprises an intravenous administration of carboplatin, wherein the administration is repeated every 7 days. In aspects, the SOC treatment comprises an intravenous administration of pembrolizumab, wherein the administration is repeated every 7 days.

[0031] In aspects, the administration of the virus changes the SOC from requiring administration of doxorubicin and cyclophosphamide (AC) to not requiring administration of AC. In aspects, the SOC treatment achieves pathologic complete response (pCR) without comprising administration of doxorubicin and cyclophosphamide (AC) chemotherapy, compared to the SOC for a tumor not administered the virus wherein the SOC treatment does comprise administration of AC chemotherapy to achieve pCR. As used herein, “pathologic complete response” or “pCR” refers to the absence of invasive tumor. In aspects, pCR refers to the absence of invasive tumor in the breast. In aspects, pCR refers to the absence of invasive tumor in the axillary lymph nodes. In aspects, pCR refers to the absence of invasive tumor in the breast and axillary lymph nodes.

[0032] In aspects, a goal of the claimed method is to achieve pCR while avoiding AC treatment, which is associated with significant toxicity that can adversely affect patient outcomes.

[0033] In aspects, the present disclosure provides a virus for use in a method for neoadjuvant treatment of a tumor in a subject, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2“) and progesterone receptor and estrogen receptor (HR-).

[0034] In aspects, the present disclosure provides a method of treating a tumor in a subject, the method comprising, consisting of, or essentially consisting of administering a virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR’).

[0035] As used herein, “treatment” or “treat” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop, and also includes addressing a medical condition or disease with the objective ofLeydig 775438Vyriad P-58-00312improving or stabilizing an outcome in a mammal being treated. “Treating,” “treat,” and “treatment” have grammatically corresponding meanings. In the context of cancer, the terms “treat” or “treating” or “treatment” can, among other things, refer to inducing apoptosis of cancerous cells, reducing the size of a cancerous tumor, delaying the growth of tumors, or inducing or enhancing an immune response against one or more cancerous cells, where the immune response has the effect of inducing apoptosis, reducing the size of a tumor, or the like. The terms “treat,” “treating,” “treatment,” “therapeutically effective,” “prevention,” etc. used herein do not necessarily imply 100% or complete treatment / prevention / etc. Rather, there are varying degrees, which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the virus, and programmed cell death 1 (PD-1) targeting antibody or antigen binding fragment thereof as described herein and methods as described herein can provide any amount of any level of treatment. Furthermore, the treatment provided by the disclosed method can include the treatment of one or more conditions or symptoms of the disease or condition being treated.

[0036] In aspects, the present disclosure provides a virus for use in a method of sensitizing a tumor in a subject to induce an enhanced immunotherapy response, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR ).

[0037] In aspects, administration of the virus changes the SOC from requiring administration of doxorubicin and cyclophosphamide (AC) to not requiring administration of AC.

[0038] The below are certain aspects of the disclosure.

[0039] 1 A virus for use in a method for neoadjuvant treatment of a tumor in a subject, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager V1TM (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).

[0040] 2. A virus for use in a method of sensitizing a tumor in a subject to induce an enhanced immunotherapy response, the method comprising administering the virus to the subjectLeydig 775438Vyriad P-58-00313prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager V1TM (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).

[0041] 3. The virus of aspect 1 or 2, wherein administration of the virus changes the SOC from requiring administration of doxorubicin and cyclophosphamide (AC) to not requiring administration of AC.

[0042] 4. The virus of any one of aspects 1-3, wherein the virus induces inflammation in the tumor.

[0043] 5. The virus of any one of aspects 1-4, wherein the tumor has a biological response-predictive subtype of immune low or negative.

[0044] 6. The virus of any one of aspects 1-5, wherein the tumor has a biological response-predictive subtype of DNA repair deficiency (DRD) low or negative.

[0045] 7 The virus of any one of aspects 1-6, wherein the virus is administered at a dose between 1E7 TCID50 and 1E11 TCID50.

[0046] 8. The virus of any one of aspects 1-6, wherein the virus is administered at a dose of 3E9 TCID50.

[0047] 9. The virus of any one of aspects 1-6, wherein the virus is administered at a dose of 3E10 TC1D50.

[0048] 10. The virus of any one of aspects 1-9, wherein the administration of the virus is repeated every 21 days.

[0049] 11 The virus of aspect 10, wherein at least two doses are administered.

[0050] 12. The virus of aspect 11, wherein at least three doses are administered.

[0051] 13. The virus of aspect 12, wherein at least four doses are administered.

[0052] 14. The virus of any one of aspects 1-13, the method comprising administering a programmed cell death 1 (PD-1) targeting antibody or antigen binding fragment thereof in combination with the virus.

[0053] 15. The virus of aspect 14, wherein the PD-1 targeting antibody or antigen binding fragment thereof is an anti -PD-1 antibody or antigen binding fragment thereof or an antiprogrammed cell death ligand 1 (PD-L1) antibody or antigen binding fragment thereof.Leydig 775438Vyriad P-58-00314

[0054] 16. The virus of aspect 14 or 15, wherein the PD-1 targeting antibody or antigen binding fragment thereof binds specifically to PD-1.

[0055] 17. The virus of aspect 14, wherein the PD-1 targeting antibody is cemiplimab, nivolumab, pembrolizumab, atezolizumab, oravelumab.

[0056] 18. The virus of any one of aspects 14-17, wherein the administration of the PD-1 targeting antibody or antigen binding fragment thereof is intravenous.

[0057] 19. The virus of any one of aspects 14-18, wherein the PD-1 targeting antibody or antigen binding fragment thereof is administered at a dose of 350 mg.

[0058] 20. The virus of any one of aspects 14-19, wherein the administration of the PD-1 targeting antibody or antigen binding fragment thereof is repeated every 21 days.

[0059] 21. The virus of aspect 20, wherein at least two doses are administered.

[0060] 22. The virus of aspect 21, wherein at least three doses are administered.

[0061] 23. The virus of aspect 22, wherein at least four doses are administered.

[0062] 24. The virus of any one of aspects 14-23, wherein the PD-1 targeting antibody is cemiplimab.

[0063] 25. The virus of any one of aspects 1-24, wherein the SOC treatment is performed at least 21 days after the administration of the virus.

[0064] 26. The virus of aspect 25, wherein the SOC treatment comprises an intravenous administration of paclitaxel at a dose of 80 mg per m2 (mg / m2), wherein the administration is repeated every 7 days.

[0065] 27. The virus of aspect 25 or 26, wherein the SOC treatment comprises an intravenous administration of carboplatin, wherein the administration is repeated every 7 days.

[0066] 28. The virus of any one of aspects 25-27, wherein the SOC treatment comprises an intravenous administration of pembrolizumab, wherein the administration is repeated every 7 days.

[0067] 29. The virus of any one of aspects 1-28, wherein the SOC treatment achieves pathologic complete response (pCR) without comprising administration of doxorubicin and cyclophosphamide (AC) chemotherapy, compared to the SOC for a tumor not administered the virus wherein the SOC treatment does comprise administration of AC chemotherapy to achieve pCR.Leydig 775438Vyriad P-58-00315

[0068] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.EXAMPLE

[0069] This example demonstrates enhanced pathologic complete response (pCR) for oncolytic viral treatment in combination with a PD-1 antibody and standard of care (SOC) treatment for certain HER2 subtypes of tumors.

[0070] As part of the I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (LSPY) clinical trial (NCT01042379), the I-SPY 2.2, which is a phase 2 platform multiple assignment randomized trial that evaluates novel agents for early breast cancer in 3 neoadjuvant sequential blocks (A / B / C) based on response predictive subtype (RPS) to achieve a pCR (FIG. 2). RPS incorporates immune (Im), DNA repair deficiency (DRD), hormone receptor (HR), and HER2 status to classify tumors into 6 subtypes (FIG. 3).

[0071] 110 Patients with anatomic stage 2 or stage 3 tumors that were HER2 and identified as high risk by MammaPrint were recruited for the trial as shown in Table 1. Patients began with Block A treatment with a combination treatment of VV1 at a dose of 3E9 TCID50 to 3E10 TCID50 administered intratumorally and cemiplimab at a dose of 350 mg administered intravenously every three weeks for up to 12 weeks, optionally followed by Block B and / or Block C treatments. Most of the 110 HER2 patients received 1-2 doses of VVl+cemiplimab before escalation to SOC treatment (FIG. 4A). Functional tumor volume (FTV) was assessed by MRI at 3 weeks and / or 6 weeks during Block A treatment and if FTV had not decreased by 30% relative to baseline a t3 weeks or by 65% relative to baseline by 6 weeks the patients were escalated early to Block B SOC treatment (FIG. 4B). SOC treatment in block B involved up to 12 weeks of weekly administration of paclitaxel for the HR+HER2 Immune DRD response-predictive subtype, and paclitaxel, carboplatin, and pembrolizumab for the HR HER2 Immune DRD , HR HER2 Immune+, and HR HER2 Immune DRD+ response-predictive subtypes. SOC treatment in block C involved up to 12 weeks of weekly administration of doxorubicin and cyclophosphamide (AC) for all response-predictive subtypes, as well as pembrolizumab administration for the HR HER2 response-predictive subtypes. Some patients predicted to have pCR by MRI / biopsy at the end of Block A or B went to surgery. pCR ratesLeydig 775438Vyriad P-58-00316were compared to dynamic control (DC) representing the best responses from historical I-SPY data (FIGS. 5A-5E).Table 1. Patient DemographicsOverall(N=110)Age (Years) Mean (SD) 54.5 (13.8)at Screening Median [Min, Max] 54.0 [26.0, 81.0] Ethnicity Hispanic / Latino 8 (7.3%)Not Hispanic / Latino 90 (81.8%)Missing 12 (10.9%)Race Asian 3 (2.7%)Black 13 (11.8%)White 78 (70.9%)Missing 15 (13.6%)Tumor Tl / 2 79 (71.8%)T3 26 (23.6%)T4 5 (4.5%)Node Negative 42 (38.2%)Positive 68 (61.8%)Response HR+HER2 1 mmune-DRD 42 (38.2%)Predictive HR HER2 Immune-DRD 24 (21.8%)Subtype (RPS) HER2- lmmune+ 34 (30.9%)HER2 Immune + (HR+) 11 (10.0%)HER2 Immune + (HRr) 23 (20.9%)HER2- lmmune-DRD+ 10 (9. 1%)HER2 lmmune-DRD+ (HR+) 1 (0.9%)HER2 Immune-DRI) (HRr) 9(8.2%)

[0072] Adverse events were characterized in patients during Block A treatment (FIG. 6A) and all Block treatments (FIG. 6B). The most common adverse events (AEs) were fatigue, nausea, headache, musculoskeletal pain, chills. Immune related AEs were also characterized for all Block treatments (FIG. 7A) as well as for individuals who received four doses of VV1 and cemiplimab during Block A (FIG. 7B) with observed hypothyroidism (n=4); adrenal insufficiency, hepatitis, rash (3 each); colitis, neutropenia (2 each); encephalitis, neuropathy, cytokine release syndrome, hyperthyroidism, diabetes, arthritis (1 each).Leydig 775438Vyriad P-58-00317

[0073] Prior to treatment with VV1 (Pre-Tx) and three weeks after treatment with VV1 (3 Weeks) patients underwent testing to titer the levels of VSV neutralizing antibody present. VSV neutralizing antibodies are produced in response to infection, and the VSV neutralizing antibody titer levels shown in Table 2 indicate that the VV1 administration resulted in successful infection. QNS indicates that the quantity of sample was not sufficient for testing.Table 2. VSV Neutralizing Antibody Titer ResultsPatient Time ResultDetectedID Point (Titer)200516 Yes Pre-Tx 1000516 Yes 3 Weeks 512000684 No Pre-Tx 000684 Yes 3 Weeks 512002584 Yes Pre-Tx 4002584 Yes 3 Weeks 16003103 No Pre-Tx 003103 Yes 3 Weeks 128003887 No Pre-Tx 003887 Yes 3 Weeks 64004525 No Pre-Tx 004525 Yes 3 Weeks 512005686 No Pre-Tx 005686 Yes 3 Weeks 128006070 No Pre-Tx 006070 Yes 3 Weeks 256007395 No Pre-Tx 007395 Yes 3 Weeks 32007713 Yes Pre-Tx 1007713 Yes 3 Weeks 64010618 No Pre-Tx 010618 Yes 3 Weeks 256013154 No Pre-Tx 013154 Yes 3 Weeks 256013771 Yes Pre-Tx 1015816 No Pre-Tx 015816 Yes 3 Weeks 16015835 No Pre-Tx 0Leydig 775438Vyriad P-58-00318Patient Time Result DetectedID Point (Titer)239144 Yes Pre-Tx 10 39144 Yes 3 Weeks 640 42135 No Pre-Tx 0 42135 Yes 3 Weeks 5120 42508 No Pre-Tx 0 42508 Yes 3 Weeks 1280 43619 Yes Pre-Tx 10 43619 Yes 3 Weeks 1280 44157 N / A Pre-Tx QNS 44157 Yes 3 Weeks 640 46250 No Pre-Tx 0 46250 Yes 3 Weeks 10240 47909 Yes 3 Weeks 640 51126 Yes Pre-Tx 14 51126 Yes 3 Weeks 640 52969 Yes Pre-Tx 10 52969 Yes 3 Weeks 640 53853 Yes Pre-Tx 14 53853 Yes 3 Weeks 2560 53865 Yes Pre-Tx 10 53865 Yes 3 Weeks 5120 55815 No Pre-Tx 0 55815 Yes 3 Weeks 5120 56818 Yes Pre-Tx 10 56818 Yes 3 Weeks 1280 57759 Yes Pre-Tx 10 57759 Yes 3 Weeks 5120 58069 No Pre-Tx 0 58069 Yes 3 Weeks 2560 61232 No Pre-Tx 0 61232 Yes 3 Weeks 160 79497 Yes 3 Weeks 1280 80385 No Pre-Tx 0 80385 Yes 3 Weeks 2560 81828 Yes Pre-Tx 20 81828 Yes 3 Weeks 64081873 No Pre-Tx 0Leydig 775438Vyriad P-58-00319Patient Time Result DetectedID Point (Titer)281873 Yes 3 Weeks 640 83154 No Pre-Tx 0 83154 Yes 3 Weeks 320 84934 No Pre-Tx 0 84934 Yes 3 Weeks 2560 85257 No Pre-Tx 0 85257 Yes 3 Weeks 1280 85791 No Pre-Tx 0 86094 No Pre-Tx 0 86094 Yes 3 Weeks 2560 88082 No Pre-Tx 0 88082 Yes 3 Weeks 1280 88103 No Pre-Tx 0 88103 Yes 3 Weeks 10240 88586 No Pre-Tx 0 15835 Yes 3 Weeks 640 18770 No Pre-Tx 0 18770 Yes 3 Weeks 5120 23695 No Pre-Tx 0 23695 Yes 3 Weeks 1280 26235 No Pre-Tx 0 26235 Yes 3 Weeks 5120 26285 No Pre-Tx 0 26285 Yes 3 Weeks 5120 30342 No Pre-Tx 0 30342 Yes 3 Weeks 2560 31088 Yes Pre-Tx 10 31088 Yes 3 Weeks 1280 31242 Yes Pre-Tx 10 31242 Yes 3 Weeks 2560 32147 Yes Pre-Tx 10 32147 Yes 3 Weeks 1280 32211 No Pre-Tx 0 32211 Yes 3 Weeks 640 32296 Yes 3 Weeks 640 33617 Yes 3 Weeks 1024034328 No Pre-Tx 0Leydig 775438Vyriad P-58-00320Patient Time Result DetectedID Point (Titer)234328 Yes 3 Weeks 2560 34879 Yes 3 Weeks 5120 38309 No Pre-Tx 0 38309 Yes 3 Weeks 640 38740 No Pre-Tx 0 38740 Yes 3 Weeks 0 61304 Yes Pre-Tx 10 61304 Yes 3 Weeks 640 63079 No Pre-Tx 0 63079 Yes 3 Weeks 640 63199 Yes Pre-Tx 14 63199 Yes 3 Weeks 1280 66073 No Pre-Tx 0 66073 Yes 3 Weeks 1280 66239 Yes Pre-Tx 160 66239 Yes 3 Weeks 320 66591 No Pre-Tx 0 66591 Yes 3 Weeks 160 67196 No Pre-Tx 0 67196 Yes 3 Weeks 2560 69637 No Pre-Tx 0 69637 Yes 3 Weeks 40 70103 Yes Pre-Tx 20 70103 Yes 3 Weeks 640 70175 No Pre-Tx 0 70175 Yes 3 Weeks 640 70775 No Pre-Tx 0 70775 Yes 3 Weeks 1280 71600 No Pre-Tx 0 71600 Yes 3 Weeks 80 72915 Yes Pre-Tx 20 72915 Yes 3 Weeks 5120 73740 No Pre-Tx 0 75228 No Pre-Tx 0 75228 Yes 3 Weeks 2560 77887 No Pre-Tx 079497 No Pre-Tx 0Leydig 775438Vyriad P-58-00321Patient Time ResultDetectedID Point (Titer)288586 Yes 3 Weeks 128089925 No Pre-Tx 089925 Yes 3 Weeks 128091529 Yes Pre-Tx 091529 Yes 3 Weeks 16092001 No Pre-Tx 092001 Yes 3 Weeks 128092345 No Pre-Tx 092345 Yes 3 Weeks 16093500 No Pre-Tx 094562 No Pre-Tx 095040 No Pre-Tx 095040 Yes 3 Weeks 128095708 Yes Pre-Tx 8096260 No Pre-Tx 096260 Yes 3 Weeks 128096827 No Pre-Tx 096827 Yes 3 Weeks 64099208 N / A Pre-Tx QNS99208 Yes 3 Weeks 64099241 Yes 3 Weeks 1280

[0074] Table 3 shows the efficacy of the VVl+cemiplimab treatment compared to DC. The VVl+cemiplimab treatment followed by SOC treatment outperformed DC in HR HER2 Im-DRD and HR+HER2 Im-DRD response-predictive subtypes (FIGS. 5B and 5C). These results show VVl+cemiplimab treatment followed by SOC treatment for HER.2 tumors of early breast cancer showed enhanced responses in Immune negative subtypes where pCR rates are low. Without wishing to be bound by theory, these results suggest that the oncolytic virus induces inflammation in the tumor, ‘priming’ it for an enhanced immunotherapy response to PD-1 antibody, and other SOC treatments resulting in an enhanced pCR (FIG. 1).Leydig 775438Vyriad P-58-00322Table 3. Efficacy of Treatment StrategyBlock where pCR Probability EstimatedSignatures N achieved estimated > pCR rate (SD)A B C DC pCR rate All subtypes 110 7 22 12 NA NAHR HER2 55 1 19 7 50.3 % (6.6) 0.04 HR+HER2 ImDRD 42 4 1 3 21.0% (6.0) 0.79 HR-HER2 ImDRD 24 0 4 6 42.9% (9.4) >0.99 HER2 Im+ 34 3 13 3 57.3% (8.1) 0.03 HER2 ImDRD+ 9 0 4 0 47.9% (14.2) 0.09

[0075] These results are the first clinical human study demonstrating intratumoral injection of a virus that sensitizes a tumor to subsequent therapy with enhanced pCR. Two prior studies have explored intratumoral oncolytic virus therapy for breast cancer; however, neither demonstrates the clinical and regulatory rigor, therapeutic integration, or strategic impact shown in the present clinical trial. Forcic et al. (“An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer,” Vaccines, 12 (958): 1-8 (2024)) reported an isolated case study in which a virologist self-administered measles and vesicular stomatitis virus (VSV) into a locally recurrent breast tumor. While tumor shrinkage and enhanced immune infiltration were observed, the virus preparations were not GMP-grade, no standard-of-care therapies were integrated or avoided, and the setting lacked formal trial design or comparative controls. Deng et al., (“Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy,” Journal of Medical Virology, 95: e28768 (2023)) disclosed preclinical data in murine models using a genetically engineered herpesvirus (VG161) with paclitaxel, demonstrating tumor shrinkage and immune activation. However, this work remains limited to animal studies and does not address the clinical potential of neoadjuvant virotherapy in humans.

[0076] In contrast, the I-SPY 2.2 trial (NCT01042379) formally evaluated a VSV-based oncolytic virus (VV1) combined with the PD-1 inhibitor cemiplimab (Cemi) in early-stage HER2-negative breast cancer patients. Administered intratumorally as a neoadjuvant therapy prior to standard systemic regimens, VV1 + Cemi was shown to prime the tumorLeydig 775438Vyriad P-58-00323microenvironment and increase rates of pathological complete response (pCR), particularly in immune-negative subtypes (e g., HR+HER2-Im-DRD- and HR-HER2-Im-DRD-). Notably, some patients achieved sufficient tumor shrinkage after VV1 + Cemi to proceed directly to surgery, bypassing anthracycline-based chemotherapy (AC). This trial is the first formal demonstration of a virus-based neoadjuvant platform capable of downstaging tumors and potentially eliminating the need for AC in defined patient subsets. The approach is distinguished by prospective trial design, subtype-specific treatment blocks, integration with immune checkpoint inhibition, and a dynamic control arm for comparative efficacy, collectively marking a clinically significant advancement over anecdotal or preclinical uses of oncolytic viruses in breast cancer.

[0077] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0078] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in theLeydig 775438Vyriad P-58-00324specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0079] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

Leydig 775438Vyriad P-58-00325CLAIMS:

1. A virus for use in a method for neoadjuvant treatment of a tumor in a subject, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).

2. A virus for use in a method of sensitizing a tumor in a subject to induce an enhanced immunotherapy response, the method comprising administering the virus to the subject prior to performing on the subject standard of care (SOC) treatment for the tumor, wherein the virus is Voyager VI™ (VV1), and wherein the tumor is triple negative for human epidermal growth factor receptor 2 (HER2-) and progesterone receptor and estrogen receptor (HR-).

3. The virus of claim 1 or 2, wherein administration of the virus changes the SOC from requiring administration of doxorubicin and cyclophosphamide (AC) to not requiring administration of AC.

4. The virus of any one of claims 1-3, wherein the virus induces inflammation in the tumor.

5. The virus of any one of claims 1-4, wherein the tumor has a biological response-predictive subtype of immune low or negative.

6. The virus of any one of claims 1-5, wherein the tumor has a biological response-predictive subtype of DNA repair deficiency (DRD) low or negative.

7. The virus of any one of claims 1-6, wherein the virus is administered at a dose between 1E7 TCID50 and 1E11 TCID50.

8. The virus of any one of claims 1-6, wherein the virus is administered at a dose of 3E9 TC1D50.

9. The virus of any one of claims 1-6, wherein the virus is administered at a dose of 3E10 TCID50.Leydig 775438Vyriad P-58-0032610. The virus of any one of claims 1-9, wherein the administration of the virus is repeated every 21 days.

11. The virus of claim 10, wherein at least two doses are administered.

12. The virus of claim 11, wherein at least three doses are administered.

13. The virus of claim 12, wherein at least four doses are administered.

14. The virus of any one of claims 1-13, the method comprising administering a programmed cell death 1 (PD-1) targeting antibody or antigen binding fragment thereof in combination with the virus.

15. The virus of claim 14, wherein the PD-1 targeting antibody or antigen binding fragment thereof is an anti-PD-1 antibody or antigen binding fragment thereof or an antiprogrammed cell death ligand 1 (PD-L1) antibody or antigen binding fragment thereof.

16. The virus of claim 14 or 15, wherein the PD-1 targeting antibody or antigen binding fragment thereof binds specifically to PD-1.

17. The virus of claim 14, wherein the PD-1 targeting antibody is cemiplimab, nivolumab, pembrolizumab, atezolizumab, or avelumab.

18. The virus of any one of claims 14-17, wherein the administration of the PD-1 targeting antibody or antigen binding fragment thereof is intravenous.

19. The virus of any one of claims 14-18, wherein the PD-1 targeting antibody or antigen binding fragment thereof is administered at a dose of 350 mg.

20. The virus of any one of claims 14-19, wherein the administration of the PD-1 targeting antibody or antigen binding fragment thereof is repeated every 21 days.

21. The virus of claim 20, wherein at least two doses are administered.

22. The virus of claim 21, wherein at least three doses are administered.

23. The virus of claim 22, wherein at least four doses are administered.

24. The virus of any one of claims 14-23, wherein the PD-1 targeting antibody is cemiplimab.Leydig 775438Vyriad P-58-0032725. The virus of any one of claims 1-24, wherein the SOC treatment is performed at least 21 days after the administration of the virus.

26. The virus of claim 25, wherein the SOC treatment comprises an intravenous administration of paclitaxel at a dose of 80 mg per m2(mg / m2), wherein the administration is repeated every 7 days.

27. The virus of claim 25 or 26, wherein the SOC treatment comprises an intravenous administration of carboplatin, wherein the administration is repeated every 7 days.

28. The virus of any one of claims 25-27, wherein the SOC treatment comprises an intravenous administration of pembrolizumab, wherein the administration is repeated every 7 days.

29. The virus of any one of claims 1-28, wherein the SOC treatment achieves pathologic complete response (pCR) without comprising administration of doxorubicin and cyclophosphamide (AC) chemotherapy, compared to the SOC for a tumor not administered the virus wherein the SOC treatment does comprise administration of AC chemotherapy to achieve pCR.